AJANTPHARM logo

Ajanta Pharma Limited Stock Price

NSEI:AJANTPHARM Community·₹300.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

AJANTPHARM Share Price Performance

₹2,431.30
-878.70 (-26.55%)
26.2% undervalued intrinsic discount
₹3,293.00
Fair Value
₹2,431.30
-878.70 (-26.55%)
26.2% undervalued intrinsic discount
₹3,293.00
Fair Value
Price ₹2,431.30
AnalystHighTarget ₹3,293.00
AnalystConsensusTarget ₹3,008.33
AnalystLowTarget ₹2,307.00

AJANTPHARM Community Narratives

AnalystHighTarget·Updated
Fair Value ₹3.29k 26.2% undervalued intrinsic discount

Expanding Asian And African Markets Will Drive Secular Growth

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value ₹3.01k 19.2% undervalued intrinsic discount

Aging Demographics And Emerging Markets Will Fuel Global Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AnalystLowTarget·Updated
Fair Value ₹2.04k 18.9% overvalued intrinsic discount

Tightening Global Regulations And Supply Risks Will Drag Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent AJANTPHARM News & Updates

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Might Deserve Your Attention Today

Aug 18
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Might Deserve Your Attention Today

Ajanta Pharma Limited (NSE:AJANTPHARM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Ajanta Pharma Limited (NSE:AJANTPHARM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Jul 30
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

May 26
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

Mar 29
If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Feb 20
What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 02
Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Ajanta Pharma Limited Key Details

₹48.1b

Revenue

₹11.5b

Cost of Revenue

₹36.5b

Gross Profit

₹27.2b

Other Expenses

₹9.3b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
74.46
Gross Margin
76.05%
Net Profit Margin
19.35%
Debt/Equity Ratio
1.3%

Ajanta Pharma Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet average dividend payer.

1 Risk
3 Rewards

About AJANTPHARM

Founded
1973
Employees
9628
CEO
Yogesh Agrawal
WebsiteView website
www.ajantapharma.com

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.5%
  • 3 Months: -1.7%
  • 1 Year: -4.7%
  • Year to Date: 0.7%
The market is up 1.5% over the last week, with the Financials sector leading the way, up 2.3%. Longer term the market is actually down 4.7% over the past year. Earnings are forecast to grow by 16% annually. Market details ›